Jpmorgan Chase & CO Aim Immuno Tech Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Aim Immuno Tech Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 127 shares of AIM stock, worth $10. This represents 0.0% of its overall portfolio holdings.
Number of Shares
127
Previous 138
7.97%
Holding current value
$10
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding AIM
# of Institutions
37Shares Held
4.83MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA2.44MShares$195,5450.0% of portfolio
-
Black Rock Inc. New York, NY698KShares$55,8610.0% of portfolio
-
Geode Capital Management, LLC Boston, MA531KShares$42,5060.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny318KShares$25,4380.0% of portfolio
-
State Street Corp Boston, MA173KShares$13,8480.0% of portfolio
About AIM ImmunoTech Inc.
- Ticker AIM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,049,300
- Market Cap $3.84M
- Description
- AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome...